Thomas A. Jr Medsger

Thomas A. Jr Medsger's AcademicInfluence.com Rankings

Philosophy

#3822

World Rank

#6113

Historical Rank

Logic

#1436

World Rank

#2187

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Thomas A. Jr Medsger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Thomas A. Jr Medsger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. (1988) (3914)
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. (1980) (3058)
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. (2013) (2731)
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. (1997) (1767)
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative (2013) (1713)
Criteria for the classification of early systemic sclerosis. (2001) (1319)
Changes in causes of death in systemic sclerosis, 1972–2002 (2007) (1305)
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease (2000) (1084)
Severe organ involvement in systemic sclerosis with diffuse scleroderma. (2000) (876)
Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. (1988) (571)
Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. (1989) (543)
Severe restrictive lung disease in systemic sclerosis. (1994) (515)
Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. (2003) (496)
The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. (1997) (437)
A disease severity scale for systemic sclerosis: development and testing. (1999) (436)
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. (2005) (435)
Incidence of systemic lupus erythematosus. Race and gender differences. (1995) (432)
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial (2010) (426)
Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. (1998) (417)
Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. (1990) (415)
A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. (1982) (380)
Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study (1994) (379)
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. (1986) (373)
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. (1984) (372)
Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. (1980) (365)
Assessment of disease severity and prognosis. (2003) (349)
Myeloablative Autologous Stem‐Cell Transplantation for Severe Scleroderma (2018) (344)
Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. (1971) (332)
Adult-onset Still's disease. Clinical course and outcome. (1987) (327)
A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. (1982) (319)
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. (2002) (311)
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. (1999) (307)
Predictors of survival in systemic sclerosis (scleroderma). (1991) (305)
D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. (1982) (304)
Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. (1995) (301)
Long-Term Outcomes of Scleroderma Renal Crisis (2000) (288)
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. (1998) (284)
Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. (2003) (274)
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. (2000) (272)
Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis (2017) (264)
Epidemiology of systemic sclerosis (scleroderma). (1971) (254)
Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. (1984) (252)
Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. (1987) (251)
Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. (1984) (250)
Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. (2000) (248)
Classification criteria for the idiopathic inflammatory myopathies. (1997) (243)
Raynaud's phenomenon: a proposal for classification. (1992) (243)
Isolated diffusing capacity reduction in systemic sclerosis. (1992) (237)
The epidemiology of polymyositis. (1970) (236)
Improvement in skin thickening in systemic sclerosis associated with improved survival. (2001) (231)
Factors predicting development of renal involvement in progressive systemic sclerosis. (1984) (221)
Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. (1984) (220)
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. (2002) (220)
Hypertension and Renal Failure (Scleroderma Renal Crisis) in Progressive Systemic Sclerosis: REVIEW OF A 25‐YEAR EXPERIENCE WITH 68 CASES (1983) (218)
The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. (1967) (217)
Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. (2003) (212)
Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis (1993) (212)
Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. (1990) (211)
Cancer and systemic sclerosis. An epidemiologic study. (1985) (210)
Normotensive renal failure in systemic sclerosis. (1989) (207)
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma (2010) (203)
Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). (1988) (197)
Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. (1992) (197)
Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. (1993) (194)
Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. (1994) (189)
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. (1998) (188)
Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. (1992) (178)
Eosinophilic fasciitis. A pathologic study of twenty cases. (1979) (178)
Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. (1986) (177)
A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. (2003) (176)
Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. (1997) (174)
Pulmonary involvement in systemic sclerosis (scleroderma). (1985) (174)
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. (2007) (163)
Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. (2003) (162)
Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. (2006) (162)
A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). (1990) (161)
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. (2010) (160)
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. (2005) (153)
Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. (1999) (147)
Palmar fasciitis and polyarthritis associated with ovarian carcinoma. (1982) (146)
Anti-SS-A antibodies and fetal outcome in maternal systemic lupus erythematosus. (1986) (146)
Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome (1986) (144)
Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. (2006) (142)
Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study (2006) (141)
Factors affecting survivorship in polymyositis. A life-table study of 124 patients. (1971) (140)
Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (2014) (137)
Anti-U3 RNP autoantibodies in systemic sclerosis. (2009) (135)
Prognostic importance of cardiac arrhythmias in systemic sclerosis. (1988) (135)
Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. (1983) (133)
Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. (2007) (133)
A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. (2012) (133)
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. (2009) (129)
Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. (2007) (127)
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. (1996) (125)
Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. (1994) (125)
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. (2009) (123)
Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. (1973) (122)
Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). (1968) (120)
Criteria for rheumatic disease. Different types and different functions. The American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. (1994) (115)
Epidemiology and natural history of systemic sclerosis. (1990) (115)
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. (1999) (115)
The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures (2009) (114)
Successful Treatment of Dry Mouth and Dry Eye Symptoms in Sjögren's Syndrome Patients With Oral Pilocarpine: A Randomized, Placebo-Controlled, Dose-Adjustment Study (2004) (114)
Fertility and pregnancy outcome in women with systemic sclerosis. (1999) (112)
Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis. (2013) (109)
Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. (2009) (109)
Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. (2009) (108)
Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. (1990) (107)
Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). (1988) (107)
Kidney disease other than renal crisis in patients with diffuse scleroderma. (2005) (107)
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. (2001) (105)
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors. (1995) (101)
Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. (1985) (101)
Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. (1987) (100)
Carpal arthritis with ankylosis in late onset Still's disease. (1976) (99)
Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. (1981) (97)
The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. (1985) (97)
D-penicillamine in the treatment of localized scleroderma. (1990) (96)
A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. (1990) (93)
Approaches for identifying and defining environmentally associated rheumatic disorders. (2000) (92)
Trigeminal neuropathy in progressive systemic sclerosis. (1982) (92)
Antiphospholipid antibodies in pediatric systemic lupus erythematosus. (1995) (91)
Validation of potential classification criteria for systemic sclerosis (2012) (90)
Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. (2005) (90)
Serum Autoantibodies and Their Clinical Associations in Patients with Childhood- and Adult-Onset Linear Scleroderma. A Single-Center Study (2008) (86)
Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. (1987) (86)
A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. (1995) (86)
The effect of D-penicillamine on pulmonary findings in systemic sclerosis. (1985) (85)
Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome. (1975) (85)
Lack of association between augmentation mammoplasty and systemic sclerosis (scleroderma). (1996) (85)
Scleroderma Renal Crisis: A Pathology Perspective (2010) (84)
The palpable tendon friction rub (1997) (83)
The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. (1997) (83)
Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. (1991) (83)
Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. (1988) (82)
T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. (1995) (81)
Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA (1995) (81)
Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. (1996) (81)
Renal biopsy findings predicting outcome in scleroderma renal crisis. (2009) (80)
Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes (2016) (80)
Treatment of systemic sclerosis with recombinant interferon‐γ. A phase I/II clinical trial (1992) (78)
Pregnancy in women with systemic sclerosis. (1989) (76)
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. (2014) (76)
The toxicity of D-penicillamine in systemic sclerosis. (1986) (75)
Cytokine production and serum levels in systemic sclerosis. (1992) (75)
Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. (1996) (73)
Risk of malignancy in women with systemic lupus erythematosus. (1995) (73)
Anti-PM-Scl antibody in patients with systemic sclerosis. (2012) (73)
Surgery for scleroderma of the hand. (1987) (71)
The rheumatic manifestaions of progressive systemic sclerosis (scleroderma). (1968) (70)
Coronary arteritis in systemic lupus erythematosus. (1976) (70)
Localization of Ro (SS-A) antigen in the cardiac conduction system. (1987) (68)
Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. (1993) (67)
Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. (1997) (67)
Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. (1989) (66)
Herpes zoster in systemic lupus erythematosus. (1995) (65)
Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. (2016) (64)
Outcome measurements in scleroderma: results from a delphi exercise. (2007) (64)
Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. (2014) (62)
Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. (2007) (61)
Epidemiology of progressive systemic sclerosis (1979) (61)
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise (2012) (60)
Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. (1993) (60)
Vasculitis in systemic sclerosis: association with Sjögren's syndrome and the CREST syndrome variant. (1987) (60)
Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele. (1994) (58)
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. (2015) (58)
Hypocalcemia associated with metastatic bone disease. A retrospective study. (1973) (57)
Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis (1990) (57)
Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: Is increased patient screening necessary? (1985) (57)
Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. (2010) (57)
Alpha1‐antitrypsin phenotypes, including M subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis (1986) (57)
The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. (1978) (56)
Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). (1986) (56)
Systemic sclerosis secondary to occupational exposure. (1988) (55)
Systemic sclerosis (scleroderma) and multiple sclerosis. (1986) (55)
Assessment of damage and activity in systemic sclerosis (2000) (54)
A controlled study of the long-term prognosis of adult Still's disease. (1995) (53)
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. (2005) (53)
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. (2004) (53)
Hydralazine induced lupus and Sweet's syndrome. Report and review of the literature. (1990) (52)
Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3. (2012) (51)
Tryptophan-induced eosinophilia-myalgia syndrome. (1990) (51)
Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma. (1984) (51)
GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. (2011) (51)
High titers of antibodies to single-stranded DNA in linear scleroderma. (1985) (50)
Serum antibody to retroviral gag proteins in systemic sclerosis. (1991) (50)
Immune complexes in progressive systemic sclerosis (scleroderma). (1982) (49)
Clinical and serological features of systemic sclerosis in a multicenter African American cohort (2017) (49)
Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. (1986) (49)
Treatment of systemic sclerosis. (1989) (49)
Factors Predicting Development of Renal Involvement in Progressive Systemic Sclerosis (1984) (48)
Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. (2000) (48)
Consensus statement on the relationship of breast implants to connective-tissue disorders. (1992) (48)
Treatment of systemic sclerosis. (1989) (47)
Epidemiology of systemic sclerosis. (1994) (46)
Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis. (2017) (45)
Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. (2001) (45)
Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). (2000) (44)
Polymyositis and dermatomyositis in children: an epidemiologic and clinical comparative analysis. (1982) (43)
Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus. (1993) (43)
Soluble serum interleukin 2 receptors in patients with systemic sclerosis. (1996) (42)
Systemic sclerosis (scleroderma) (1991) (42)
HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. (1998) (42)
Cerebrospinal fluid immune complexes in systemic lupus erythematosus involving the central nervous system. (1982) (41)
Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. (1988) (40)
Risk factors for adult Still's disease. (1996) (40)
Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. (1988) (39)
Conclusion and identification of the core set of variables to be used in clinical investigations. (2003) (39)
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry (2019) (38)
Significance of Palpable Tendon Friction Rubs in Early Diffuse Cutaneous Systemic Sclerosis (2013) (38)
Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. (1989) (38)
Scleromyxedema myopathy: case report and review of the literature. (1988) (37)
Derivation and Validation of a Prediction Rule for Two‐Year Mortality in Early Diffuse Cutaneous Systemic Sclerosis (2014) (36)
Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes. (1999) (36)
An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera. (1999) (35)
Previous Pregnancy Outcome Is an Important Determinant of Subsequent Pregnancy Outcome in Women With Systemic Lupus Erythematosus (1992) (35)
Analysis of Soluble and Cell Surface Factors Regulating Anti-DNA Topoisomerase I Autoantibody Production Demonstrates Synergy Between Th1 and Th2 Autoreactive T Cells1 (2000) (35)
Progressive systemic sclerosis. (1983) (35)
Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. (2001) (35)
The assessment of the patient with systemic sclerosis. Introduction. (2003) (34)
Allergic granulomatous angiitis (Churg-Strauss syndrome). (1975) (34)
Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis (2013) (33)
HLA-DR antigens in progressive systemic sclerosis (scleroderma). (1983) (32)
Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides. (1995) (32)
HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies. (1995) (32)
Microsurgical revascularisation of the hand in scleroderma. (1987) (31)
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial. (2021) (29)
Circulating immune complexes in eosinophilic fasciitis. (1982) (29)
Communicating hydrocephalus secondary to diffuse meningeal spread of Wegener's granulomatosis: case report and literature review. (1998) (28)
Resorption of the mandibular condyles and coronoid processes in progressive systemic sclerosis (scleroderma). (1981) (28)
Anemia and scleroderma: frequency, causes, and marrow findings. (1968) (27)
Anti–RNPC‐3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate‐to‐Severe Gastrointestinal Dysmotility (2019) (24)
A new look at the epidemiology of ankylosing spondylitis and related syndromes. (1979) (24)
Newly identified U4/U6 snRNP-binding proteins by serum autoantibodies from a patient with systemic sclerosis. (1991) (23)
Study of 102 Consecutive Cases with Functional Correlations and Review of the Literature (1985) (23)
Brachial plexitis mimicking C5 radiculopathy--a presentation of giant cell arteritis. (1983) (22)
Integrative analysis of DNA methylation in discordant twins unveils distinct architectures of systemic sclerosis subsets (2019) (22)
Alpha 1-antitrypsin phenotypes, including M subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. (1986) (22)
T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. (2006) (20)
Myasthenia gravis and scleroderma: Two cases and a review of the literature (2007) (20)
1972-2002in causes of death in systemic sclerosis, (2007) (20)
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. (2017) (20)
Quality indicator set for systemic sclerosis. (2011) (20)
Molecular Recognition Patterns of Serum Anti-DNA Topoisomerase I Antibody in Systemic Sclerosis1 (2004) (20)
Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. (1992) (20)
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry (2018) (19)
L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak. (1992) (19)
Anti-U5 small nuclear ribonucleoprotein (snRNP) antibodies: a rare anti-U snRNP specificity. (1996) (19)
Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. (1992) (18)
Autoantibodies and Their Role in Scleroderma Clinical Care (2016) (18)
Reduced natural killer cell activity in patients with systemic sclerosis. Correlation with clinical disease type. (1988) (18)
Photopheresis for scleroderma? No! (1992) (18)
Disease Subsets in Clinical Practice (2012) (18)
Serum amyloid A protein concentration in progressive systemic sclerosis (scleroderma). (1984) (17)
14‐3‐3z sequesters cytosolic T‐bet, upregulating IL‐13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma (2017) (17)
Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. (1985) (17)
Serum eosinophilotactic activity in eosinophilic fasciitis. (1982) (17)
D-penicillamine in systemic sclerosis? Yes! (2001) (16)
Progress in the Evolution of Systemic Sclerosis Classification Criteria and Recommendation for Additional Comparative Specificity Studies (2015) (15)
D-penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma). (1987) (15)
Novel human autoantibodies reactive with 5'-terminal trimethylguanosine cap structures of U small nuclear RNA. (1992) (15)
Classification and diagnostic criteria for polymyositis and dermatomyositis. (1995) (14)
Brief Report: HLA–DRB1, DQA1, and DQB1 in Juvenile‐Onset Systemic Sclerosis (2016) (14)
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. (2001) (14)
Reduced T lymphoid colony growth in patients with progressive systemic sclerosis and rheumatoid arthritis. (1982) (13)
Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival (2019) (13)
Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma) (1982) (13)
Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. (2001) (13)
The future status of pediatric rheumatology in the United States: strategic planning for the year 2000. American College of Rheumatology Blue Ribbon Committee for Academic Pediatric Rheumatology. (2000) (12)
Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis (2021) (12)
The variability of immunologic laboratory tests. (1982) (12)
Localized scleroderma and regional inflammatory myopathy (2014) (11)
Wrist drop in progressive systemic sclerosis (scleroderma): complete rupture of the extensor tendon mechanism. (1985) (11)
Severe arthralgias after wide fluctuation in corticosteroid dosage. (1986) (10)
Identification of Autoantibodies to RNA Polymerase 11 Occurrence in Systemic Sclerosis and Association with Autoantibodies to RNA Polymerases (2013) (10)
Discordance of SSA/Ro and SSB/La cellular antigens in synchronized cells. (1986) (10)
History of skin thickness assessment and the Rodnan skin thickness scoring method in systemic sclerosis (2019) (10)
Serum immunoglobulins, rheumatoid factor, and pneumoconiosis in coal miners with rheumatoid arthritis. (1976) (9)
Brief Report: Whole‐Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans (2018) (9)
Rationale for and efficacy of digital arterial reconstruction in scleroderma: report of two cases. (2002) (9)
Muscle cramps associated with localized scleroderma skin lesions: focal dystonia, neuromyotonia, or nerve entrapment? (2006) (9)
Cholestasis associated with D-penicillamine therapy: case report and review of the literature. (1981) (8)
IL-13-producing CD 8 + T cells mediate dermal fibrosis in patients with systemic sclerosis (2013) (7)
A Novel Protein Highly Expressed in Testis Is Overexpressed in Systemic Sclerosis Fibroblasts and Targeted by Autoantibodies 1 (2003) (7)
Lipid microspherule-associated acute monarticular arthritis. (1986) (7)
Over one-third of Th/To antibody positive scleroderma patients develop pulmonary hypertension in long-term follow-up. (2022) (7)
Systemic sclerosis and malignancy--are they related? (1985) (7)
Connective tissue diseases: Predicting death in SSc: planning and cooperation are needed (2011) (7)
Preliminary classification criteria for systemic sclerosis in children. (2005) (7)
The Association of Progressive Systemic Sclerosis (Sclerodenna) with Coal Miners?? Pneumoeoniosis and Other Forms of Silicosis (1967) (6)
Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. (2021) (6)
Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension (2019) (6)
Correlation between ANA determinations on tissue substrate, WiL-2 cell substrate, and precipitin antibody by double diffusion. (1987) (5)
Proceedings: HL-A antigen 27 and psoriatic spondylitis. (1974) (5)
Elevated serum soluble interleukin-2 receptor levels in subacute cutaneous lupus erythematosus. (1993) (5)
Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements. (1994) (5)
rheumatism collaborative initiative rheumatology / European league against sclerosis : an American college of 2013 classification criteria for systemic (2013) (4)
RNA Polymerase I-III Autoantibodies (1996) (4)
Localized Expression of Tenascin in Systemic Sclerosis-Associated Lung Fibrosis and its Regulation by IGF Binding Protein (IGFBP)-3 (2012) (4)
A novel cell-cycle-dependent 350-kDa nuclear protein: C-terminal domain sufficient for nuclear localization. (1995) (4)
Minimally Important Difference in Diffuse Systemic Sclerosis (2006) (3)
The Clinical Aspects of Autoantibodies (2017) (3)
The Frequency of the Rheumatic Diseases (1972) (3)
Integrative analysis of DNA methylation in discordant twins unveils distinct architectures of systemic sclerosis subsets (2019) (3)
We need simple guidelines for reporting rates of rheumatic diseases. (1999) (2)
Two Scleroderma Patients with Differing Patterns of Muscle Disease (2011) (2)
Synergy Between Th 1 and Th 2 Autoreactive Autoantibody Production Demonstrates Regulating Anti-DNA Topoisomerase I Analysis of Soluble and Cell Surface Factors (2000) (2)
The Lupus Foundation as an additional source for case ascertainment: developing a community-based lupus registry. (2000) (2)
Response of patients with renal involvement by progressive systemic sclerosis to antihypertensive therapy. (1981) (2)
Specificity of the hydrochloric-acid-modified Crithidia luciliae immunofluorescence assay for detection of antibody to native DNA. (1987) (2)
Hematopoietic Stem Cell Transplantation for Systemic Sclerosis (2019) (2)
Sjögren’s Syndrome and Systemic Sclerosis (Scleroderma) (1987) (2)
Treatment of systemic sclerosis. (1989) (1)
Development of Pulmonary Hypertension in Over One‐Third of Patients With Th/To Antibody–Positive Scleroderma in Long‐Term Follow‐Up (2022) (1)
AB0727 There is a Need for New Systemic Sclerosis Subset Criteria. A Content Analytic Approach (2015) (1)
Treatment of systemic sclerosis. (1990) (1)
Current Management of Polymyositis and Dermatomyositis (1989) (1)
Commentary on myofascial release therapy in systemic lupus erythematosus and scleroderma. (2012) (1)
Gastric Antral Vascular Ectasia in Scleroderma: A Single Center Experience (2011) (1)
A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials. (2022) (1)
Scleroderma renal crisis: a high index of suspicion speeds diagnosis and life-saving treatment. (2006) (1)
Systemic Sclerosis (Scleroderma) and Raynaud’s Phenomenon (2009) (1)
Natural killer cell numbers in systemic sclerosis (1987) (0)
Personalized Gene Expression Profile Information Predicts Severity of Systemic Sclerosis Despite Heterogeneity of Disease (2018) (0)
The diffuse form of scleroderma is associated with DRB1 1104 (1991) (0)
Analysis of T-Cell Repertoire before and 21 Days after Autologous Peripheral Blood Stem Cell Transplantation for Systemic Sclerosis. (2004) (0)
Gerald P. Rodnan, 1927–1983 (1984) (0)
Fibroblasts and Targeted by Autoantibodies Overexpressed in Systemic Sclerosis A Novel Protein Highly Expressed in Testis Is (2003) (0)
Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance (2021) (0)
Case report Myasthenia gravis and scleroderma: Two cases and a review of the literature (2007) (0)
3420 Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival (2019) (0)
Reply (2017) (0)
Inflammatory myopathies. (1995) (0)
Survival with Systemic Sclerosis (Scleroderma) (2020) (0)
AB0840 Scleroderma classification criteria: Disease-specific methods for valid case comparisons (2013) (0)
19 – Enfermedades reumatológicas (2007) (0)
Lead Authors and Contributors (2010) (0)
Systemic Sclerosis Anti-DNA Topoisomerase I Antibody in Molecular Recognition Patterns of Serum (2004) (0)
Intensive Immunosuppression Plus T-Cell Depleted Autologous Peripheral Blood Stem Cell Transplantation for Systemic Sclerosis. (2004) (0)
Discrepancies betweenin vivo andin vitro responses toCandida antigen in patients with progressive systemic sclerosis (PSS; scleroderma) (1981) (0)
HLA contributions to risk and protection for anti-centromere autoantibody-positive scleroderma (2018) (0)
Molecular aspects of IL-13 up-regulation by CD8+ T cells from systemic sclerosis patients (BA3P.132) (2014) (0)
Reply for “Derivation and External Validation of a Prediction Rule for Five‐Year Mortality in Patients with Early Diffuse Cutaneous Scleroderma” (2016) (0)
The Journal of Rheumatology Localized Scleroderma Outcome Measures Assessment of Disease Activity: A Work in Progress Toward Development of The Localized Scleroderma Skin Severity Index and Physician Global (2009) (0)
Dr Leroy's contribution to the understanding of systemic sclerosis. (2004) (0)
Clinical and Serologic Patients Subsets in Scleroderma(第167回北里医学会招待学術講演会要旨) (1992) (0)
NUCLEOLAR ANTIGEN PM-Scl (2005) (0)
Proceedings: Selective carpo-metacarpal arthritis with early ankylosis in adult onset Still's disease. (1975) (0)
Hypocalcemia Associated With Metastatic Bone Disease (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas A. Jr Medsger?

Thomas A. Jr Medsger is affiliated with the following schools:

Thomas A. Jr Medsger's Academic­Influence.com Rankings

Why Is Thomas A. Jr Medsger Influential?

Thomas A. Jr Medsger's Published Works

Published Works

What Schools Are Affiliated With Thomas A. Jr Medsger?

Thomas A. Jr Medsger's AcademicInfluence.com Rankings